ERBB2 and cancer: Based on these data, we hypothesized that adding an anti-HER2 monoclonal antibody to dalpiciclib and pyrotinib might further prolong PFS in HR-negative and HER2-positive subset, while in HR-positive and HER2-positive cancer, the addition of endocrine therapy might be beneficial.